HRP20200614T1 - Pripravci koji sadrže amlodipin i bisoprolol - Google Patents
Pripravci koji sadrže amlodipin i bisoprolol Download PDFInfo
- Publication number
- HRP20200614T1 HRP20200614T1 HRP20200614TT HRP20200614T HRP20200614T1 HR P20200614 T1 HRP20200614 T1 HR P20200614T1 HR P20200614T T HRP20200614T T HR P20200614TT HR P20200614 T HRP20200614 T HR P20200614T HR P20200614 T1 HRP20200614 T1 HR P20200614T1
- Authority
- HR
- Croatia
- Prior art keywords
- packaged
- dosage form
- amlodipine
- moisture
- blister
- Prior art date
Links
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 title claims 7
- 229960000528 amlodipine Drugs 0.000 title claims 3
- VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 title 1
- 229960002781 bisoprolol Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000002552 dosage form Substances 0.000 claims 10
- 238000002360 preparation method Methods 0.000 claims 10
- -1 polypropylene Polymers 0.000 claims 9
- RZPZLFIUFMNCLY-WLHGVMLRSA-N (e)-but-2-enedioic acid;1-(propan-2-ylamino)-3-[4-(2-propan-2-yloxyethoxymethyl)phenoxy]propan-2-ol Chemical compound OC(=O)\C=C\C(O)=O.CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 RZPZLFIUFMNCLY-WLHGVMLRSA-N 0.000 claims 8
- 229960005400 bisoprolol fumarate Drugs 0.000 claims 8
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 7
- 229910052782 aluminium Inorganic materials 0.000 claims 7
- 239000002775 capsule Substances 0.000 claims 7
- 239000002131 composite material Substances 0.000 claims 7
- 239000010408 film Substances 0.000 claims 7
- 239000004743 Polypropylene Substances 0.000 claims 6
- 229920001155 polypropylene Polymers 0.000 claims 6
- 239000013039 cover film Substances 0.000 claims 5
- 239000007884 disintegrant Substances 0.000 claims 5
- 239000000314 lubricant Substances 0.000 claims 5
- ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 claims 4
- 229960004005 amlodipine besylate Drugs 0.000 claims 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 4
- 238000004806 packaging method and process Methods 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000007787 solid Substances 0.000 claims 4
- 239000004698 Polyethylene Substances 0.000 claims 3
- 230000000181 anti-adherent effect Effects 0.000 claims 3
- 239000011230 binding agent Substances 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 239000000945 filler Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 229920000573 polyethylene Polymers 0.000 claims 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
- 229920002472 Starch Polymers 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims 2
- 239000011888 foil Substances 0.000 claims 2
- 239000011521 glass Substances 0.000 claims 2
- 235000019359 magnesium stearate Nutrition 0.000 claims 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- 239000008107 starch Substances 0.000 claims 2
- 235000019698 starch Nutrition 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000853 adhesive Substances 0.000 claims 1
- 239000006059 cover glass Substances 0.000 claims 1
- 238000007907 direct compression Methods 0.000 claims 1
- 239000007903 gelatin capsule Substances 0.000 claims 1
- 238000000265 homogenisation Methods 0.000 claims 1
- 239000011256 inorganic filler Substances 0.000 claims 1
- 229910003475 inorganic filler Inorganic materials 0.000 claims 1
- 239000012766 organic filler Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Packages (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Peptides Or Proteins (AREA)
Claims (10)
1. Ambalažirani oblik doziranja, naznačen time što sadrži
i) homogeni stabilni čvrsti farmaceutski pripravak koji sadrži amlodipin-besilat, bisoprolol-fumarat, organska ili anorganska punila, sredstva za raspadanje, maziva, antiadhezive i izborno vezivo, koji dodatno sadrži manje od 0,5% spoja formule
[image]
na osnovi težine aktivnih sastojaka,
ii) gdje je homogeni pripravak u obliku tablete ili kapsule,
iii) tabletu ili kapsulu ambalažiranu u ambalažu otpornu na vlagu,
iv) gdje se ambalažu otpornu na vlagu bira iz skupine koju čine hladno oblikovani blister načinjen od kompozitne folije pokrivene aluminijskom pokrovnom folijom, gdje se blister pripravlja iz kompozitne folije koju se može toplinski oblikovati otporne na vlagu, pokrivene aluminijskom pokrovnom folijom, i staklena ili polipropilenska posuda koja ima poklopac od polietilena ili polipropilena nepropustan za zrak.
2. Ambalažirani oblik doziranja u skladu s patentnim zahtjevom 1, naznačen time što homogeni pripravak sadrži manje od 0,3% spoja formule (3).
3. Ambalažirani oblik doziranja u skladu s patentnim zahtjevom 1, naznačen time što homogeni pripravak sadrži manje od 0,2% spoja formule (3).
4. Ambalažirani oblik doziranja u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što se tabletu ambalažira u ambalažu otpornu na vlagu, gdje homogeni pripravak sadrži 2%-20%, po mogućnosti 2%-10%, poželjnije, 1-6% amlodipin-besilata, 2%-20%, po mogućnosti 2%-10%, poželjnije 1%-6% bisoprolol-fumarata, koji dodatno sadrži 60%-90%, po mogućnosti 70%-90%, poželjnije 80%-90% punila, 1%-10%, po mogućnosti 4%-6% sredstva za raspadanje, 0,5%-3%, po mogućnosti 1%-2% maziva, 0,3%-2%, po mogućnosti 0,1%-5% veziva na osnovi težine tablete.
5. Ambalažirani oblik doziranja u skladu s patentnim zahtjevom 4, naznačen time što se tabletu ambalažira u hladno oblikovani blister (tzv. hladni blister /CFF/) od OPA/AL/PVC kompozitne folije, pokrivene aluminijskom pokrovnom folijom, ili u blister od kompozitne folije koju se može toplinski oblikovati otporne na vlagu i pokrivene aluminijskom pokrovnom folijom, ili u staklenu ili polipropilensku posudu opremljenu poklopcem od polietilena ili polipropilena za spremnike nepropustnim za zrak, gdje homogeni pripravak sadrži 1%-6% amlodipin-besilata, 1%-6% bisoprolol-fumarata, 80%-90% mikrokristalne celuloze, 4%-6% karboksimetilškrob-natrija, 1%-2% magnezijevog stearata, 0,5%-1% koloidnog silicijevog dioksida na osnovi težine tablete.
6. Ambalažirani oblik doziranja u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time što je ambalaža otporna na vlagu OPA/AL/PVC kompozitna folija, pokrivena aluminijskom pokrovnom folijom.
7. Ambalažirani oblik doziranja u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što se kapsulu ambalažira u hladno oblikovani blister (tzv. hladni blister /CFF/) od OPA/AL/PVC kompozitne folije, pokrivene aluminijskom pokrovnom folijom, ili u blister od kompozitne folije koju se može toplinski oblikovati otporne na vlagu i pokrivene aluminijskom pokrovnom folijom, ili u staklenu ili polipropilensku posudu opremljenu poklopcem od polietilena ili polipropilena za spremnike nepropusnim za zrak, gdje homogeni pripravak sadrži 10%-15% amlodipin-besilata, 10%-15% bisoprolol-fumarata, dodatno 55%-65% mikrokristalne celuloze, 4%-6% karboksimetilškrob-natrija, 1%-2% magnezijevog stearata, 0,5%-1% koloidnog silicijevog dioksida na osnovi težine tvari za punjenje kapsule.
8. Postupak priprave stabilnog čvrstog ambalažiranog oblika doziranja koji sadrži homogeni pripravak koji sadrži amlodipinsku bazu, ili njezinu farmaceutski prihvatljivu sol, i bisoprolol-fumarat, naznačen time što se amlodipinsku bazu, ili njezinu farmaceutski prihvatljivu sol, i bisoprolol-fumarat, sredstvo za raspadanje, mazivo i po potrebi dodatne pomoćne tvari koje se upotrebljava u farmaceutskoj industriji homogenizira, zatim se dodaje antiadheziv, nastavi se s homogeniziranjem, zatim se
a.) homogenizat komprimira u tablete postupkom izravnog komprimiranja ili,
b.) homogenizat puni u tvrde želatinske kapsule na poznati način,
zatim se dobivene tablete ili kapsule ambalažira u zaštitna pakiranja otporna na vlagu na poznati način.
9. Postupak priprave stabilnog čvrstog ambalažiranog oblika doziranja u obliku tableta u skladu s patentnim zahtjevom 8, naznačen time što se za homogeni pripravak na osnovi težine tableta upotrebljava 2%-20%, po mogućnosti 2%-10%, poželjnije 1-6% amlodipinske baze, ili njezine farmaceutski prihvatljive adicijske soli s kiselinom, po mogućnosti amlodipin-besilata, 2%-20%, po mogućnosti 2%-10%, poželjnije 1%-6% bisoprolol-fumarata, dodatno 60%-90%, po mogućnosti 70%-90%, poželjnije 80%-90% punila, 1%-10%, po mogućnosti 4%-6% sredstva za raspadanje, 0,5%-3%, po mogućnosti 1%-2% maziva, 0,3%-2%, po mogućnosti 1%-10%, po mogućnosti 0,5%-1% veziva.
10. Postupak priprave stabilnog čvrstog ambalažiranog oblika doziranja u obliku kapsula u skladu s patentnim zahtjevom 8, naznačen time što se za homogeni pripravak na osnovi težine tvari za punjenje kapsule upotrebljava 5%-80%, po mogućnosti 5%-18%, poželjnije, 10-15% amlodipinske baze, ili njezine farmaceutski prihvatljive adicijske soli s kiselinom, po mogućnosti amlodipin-besilata, 5%-80%, po mogućnosti 5%-15%, poželjnije 10%-15% bisoprolol-fumarata, dodatno 1%-10%, po mogućnosti 4%-6% sredstva za raspadanje, 0,5%-3%, po mogućnosti 1%-2% maziva, 0,3%-2%, po mogućnosti 0,5%-1% of antiadheziv agent, i po potrebi 10%-90%, po mogućnosti 45%-75%, poželjnije 55%-65% punila.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0800591A HU230877B1 (hu) | 2008-09-30 | 2008-09-30 | Stabil kombinációs gyógyszerkészítmény |
| EP11003486.5A EP2359815B1 (en) | 2008-09-30 | 2009-09-30 | Compositions comprising amlodipine and bisoprolol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20200614T1 true HRP20200614T1 (hr) | 2020-10-02 |
Family
ID=89988527
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20110162AA HRP20110162B1 (hr) | 2008-09-30 | 2011-03-04 | Spojevi koji sadrže amlodipin i bisoprolol |
| HRP20191373 HRP20191373T1 (hr) | 2008-09-30 | 2019-07-31 | Pripravci koji sadrže amlodipin i bisoprolol |
| HRP20200614TT HRP20200614T1 (hr) | 2008-09-30 | 2020-04-08 | Pripravci koji sadrže amlodipin i bisoprolol |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20110162AA HRP20110162B1 (hr) | 2008-09-30 | 2011-03-04 | Spojevi koji sadrže amlodipin i bisoprolol |
| HRP20191373 HRP20191373T1 (hr) | 2008-09-30 | 2019-07-31 | Pripravci koji sadrže amlodipin i bisoprolol |
Country Status (31)
| Country | Link |
|---|---|
| EP (2) | EP2359815B1 (hr) |
| KR (1) | KR101772619B1 (hr) |
| CN (1) | CN102164585B (hr) |
| AT (2) | AT510866A3 (hr) |
| BG (1) | BG66274B1 (hr) |
| CH (1) | CH702345B1 (hr) |
| CY (1) | CY1122084T1 (hr) |
| CZ (2) | CZ30825U1 (hr) |
| DE (1) | DE202009019152U1 (hr) |
| DK (1) | DK2344141T3 (hr) |
| EA (2) | EA026238B9 (hr) |
| EE (1) | EE05723B1 (hr) |
| ES (2) | ES2739900T3 (hr) |
| GE (1) | GEP20135859B (hr) |
| HK (1) | HK1155976A1 (hr) |
| HR (3) | HRP20110162B1 (hr) |
| HU (3) | HU230877B1 (hr) |
| LT (3) | LT2344141T (hr) |
| ME (1) | ME03774B (hr) |
| MX (1) | MX2011003407A (hr) |
| MY (1) | MY175270A (hr) |
| PL (3) | PL2359815T3 (hr) |
| PT (3) | PT2359815T (hr) |
| RO (1) | RO127490B1 (hr) |
| RS (3) | RS60784B1 (hr) |
| RU (2) | RU2549437C2 (hr) |
| SG (1) | SG194392A1 (hr) |
| SI (2) | SI2344141T1 (hr) |
| SK (2) | SK288593B6 (hr) |
| UA (1) | UA101407C2 (hr) |
| WO (1) | WO2010038091A2 (hr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU230877B1 (hu) | 2008-09-30 | 2018-11-29 | EGIS Gyógyszergyár NyR | Stabil kombinációs gyógyszerkészítmény |
| CN101766611B (zh) * | 2010-02-09 | 2011-10-12 | 施慧达药业集团(吉林)有限公司 | 一种左旋氨氯地平或其可药用盐和β受体阻滞剂的药物组合物及其应用 |
| US20150094345A1 (en) | 2012-02-17 | 2015-04-02 | Egis Gyogyszergyar Zrt. | Pharmaceutical formulation having improved stability |
| CN114404414A (zh) * | 2013-06-13 | 2022-04-29 | 阿克比治疗有限公司 | 用于治疗贫血症的组合物和方法 |
| HUP1300496A2 (hu) | 2013-08-16 | 2015-03-02 | Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag | Stabil kombinációs gyógyszerkészítmény |
| FR3027803B1 (fr) * | 2014-11-05 | 2018-02-09 | Les Laboratoires Servier | Composition pharmaceutique comprenant un betabloquant et un inhibiteur de l'enzyme de conversion |
| FR3050380B1 (fr) | 2016-04-20 | 2020-07-10 | Les Laboratoires Servier | Composition pharmaceutique comprenant un betabloquant, un inhibiteur de l'enzyme de conversion et un antihypertenseur ou un ains. |
| WO2024052498A1 (en) | 2022-09-07 | 2024-03-14 | Kinast Lasse | An immediate-release oral pharmaceutical form of amlodipine with increased api content |
| CN116687926B (zh) * | 2023-07-27 | 2023-12-12 | 石家庄四药有限公司 | 一种比索洛尔氨氯地平复方片剂及其制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU221810B1 (hu) * | 1997-08-12 | 2003-01-28 | EGIS Gyógyszergyár Rt. | Eljárás amlodipin-bezilát előállítására és az eljárás intermedierjei |
| GB0001621D0 (en) * | 2000-01-26 | 2000-03-15 | Astrazeneca Ab | Pharmaceutical compositions |
| AT5874U1 (de) * | 2000-12-29 | 2003-01-27 | Bioorg Bv | Pharmazeutische zubereitungen enthaltend amlodipinmaleat |
| EP1309556B1 (en) | 2000-12-29 | 2004-11-24 | Pfizer Limited | Amlodipine fumarate |
| AU2001100431A4 (en) * | 2001-10-03 | 2001-11-01 | Pfizer Limited | Pharmaceutical compositions comprising amlodipine maleate |
| WO2003032954A1 (en) | 2001-10-17 | 2003-04-24 | Dr. Reddy's Laboratories Ltd. | Stabilized pharmaceutical formulations containing amlodipine maleate |
| WO2004075825A2 (en) * | 2003-02-28 | 2004-09-10 | Ranbaxy Laboratories Limited | Dosage forms of amlodipine and processes for their preparation |
| WO2005051350A2 (en) * | 2003-10-28 | 2005-06-09 | Torrent Pharmaceuticals Limited | Water dispersible tablet |
| WO2005099699A1 (en) * | 2004-04-07 | 2005-10-27 | Sepracor Inc. | Combination of (s)-amlodipine and a beta-blocker, and methods for reducing hypertension |
| IN224215B (hr) * | 2004-08-05 | 2009-02-06 | ||
| WO2006059217A1 (en) * | 2004-12-01 | 2006-06-08 | Ranbaxy Laboratories Limited | Stable solid dosage forms of amlodipine besylate and processes for their preparation |
| CZ2005141A3 (cs) * | 2005-03-07 | 2006-04-12 | Lunaria, Spol. S. R. O. | Lécivý prípravek na bázi amlodipin-besilátu se zvýsenou stabilitou |
| IES20070122A2 (en) * | 2006-12-05 | 2008-05-28 | Michael Hilary Burke | A process for the preparation of an orally administered unit dose tablet |
| HU230877B1 (hu) | 2008-09-30 | 2018-11-29 | EGIS Gyógyszergyár NyR | Stabil kombinációs gyógyszerkészítmény |
-
2008
- 2008-09-30 HU HU0800591A patent/HU230877B1/hu unknown
-
2009
- 2009-09-30 WO PCT/HU2009/000085 patent/WO2010038091A2/en active Application Filing
- 2009-09-30 PL PL11003486T patent/PL2359815T3/pl unknown
- 2009-09-30 EP EP11003486.5A patent/EP2359815B1/en not_active Revoked
- 2009-09-30 SI SI200931990T patent/SI2344141T1/sl unknown
- 2009-09-30 RS RS20200397A patent/RS60784B1/sr unknown
- 2009-09-30 DK DK09748467.9T patent/DK2344141T3/da active
- 2009-09-30 ES ES09748467T patent/ES2739900T3/es active Active
- 2009-09-30 CN CN200980138060.7A patent/CN102164585B/zh active Active
- 2009-09-30 EA EA201100430A patent/EA026238B9/ru not_active IP Right Cessation
- 2009-09-30 RS RS20110136A patent/RS60686B1/sr unknown
- 2009-09-30 PL PL394605A patent/PL394605A1/pl unknown
- 2009-09-30 PT PT110034865T patent/PT2359815T/pt unknown
- 2009-09-30 ES ES201190015A patent/ES2385988B2/es active Active
- 2009-09-30 LT LTEP09748467.9T patent/LT2344141T/lt unknown
- 2009-09-30 RU RU2011112047/15A patent/RU2549437C2/ru active
- 2009-09-30 PT PT09748467T patent/PT2344141T/pt unknown
- 2009-09-30 GE GEAP200912210A patent/GEP20135859B/en unknown
- 2009-09-30 PT PT2009000085A patent/PT2010038091Y/pt active IP Right Grant
- 2009-09-30 AT ATA9359/2009A patent/AT510866A3/de active IP Right Grant
- 2009-09-30 ME MEP-2020-76A patent/ME03774B/me unknown
- 2009-09-30 SI SI200932053T patent/SI2359815T1/sl unknown
- 2009-09-30 CZ CZ2017-33281U patent/CZ30825U1/cs not_active IP Right Cessation
- 2009-09-30 KR KR1020117009405A patent/KR101772619B1/ko active IP Right Grant
- 2009-09-30 RU RU2014139476A patent/RU2687282C2/ru active
- 2009-09-30 DE DE202009019152.4U patent/DE202009019152U1/de not_active Expired - Lifetime
- 2009-09-30 EE EEP201100029A patent/EE05723B1/et unknown
- 2009-09-30 UA UAA201105446A patent/UA101407C2/ru unknown
- 2009-09-30 MY MYPI2011001388A patent/MY175270A/en unknown
- 2009-09-30 RO RO201100274A patent/RO127490B1/ro unknown
- 2009-09-30 SG SG2013073382A patent/SG194392A1/en unknown
- 2009-09-30 CH CH00567/11A patent/CH702345B1/de unknown
- 2009-09-30 EA EA201691869A patent/EA038392B1/ru unknown
- 2009-09-30 PL PL09748467T patent/PL2344141T3/pl unknown
- 2009-09-30 RS RSP20190990 patent/RS59201B1/sr unknown
- 2009-09-30 HU HUE11003486A patent/HUE049948T2/hu unknown
- 2009-09-30 CZ CZ2011-252A patent/CZ308237B6/cs unknown
- 2009-09-30 SK SK5023-2011A patent/SK288593B6/sk unknown
- 2009-09-30 HU HUE09748467A patent/HUE045326T2/hu unknown
- 2009-09-30 AT ATGM8014/2015U patent/AT14769U1/de not_active IP Right Cessation
- 2009-09-30 SK SK7-2017U patent/SK7997Y1/sk unknown
- 2009-09-30 LT LTEP11003486.5T patent/LT2359815T/lt unknown
- 2009-09-30 MX MX2011003407A patent/MX2011003407A/es not_active Application Discontinuation
- 2009-09-30 EP EP09748467.9A patent/EP2344141B1/en not_active Revoked
-
2011
- 2011-02-24 LT LT2011012A patent/LT5815B/lt unknown
- 2011-03-04 HR HRP20110162AA patent/HRP20110162B1/hr active IP Right Grant
- 2011-04-29 BG BG10110927A patent/BG66274B1/bg unknown
- 2011-10-03 HK HK11110411.7A patent/HK1155976A1/zh unknown
-
2019
- 2019-07-30 CY CY20191100810T patent/CY1122084T1/el unknown
- 2019-07-31 HR HRP20191373 patent/HRP20191373T1/hr unknown
-
2020
- 2020-04-08 HR HRP20200614TT patent/HRP20200614T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200614T1 (hr) | Pripravci koji sadrže amlodipin i bisoprolol | |
| MX2011003510A (es) | Metodo para fabricar un laminado adhesivo de multiples capas. | |
| JP5190159B1 (ja) | 医薬 | |
| JP2018076372A (ja) | アナグリプチン含有固形製剤 | |
| AU2014203766B2 (en) | Pack of medicinal tablets | |
| RU2015144543A (ru) | Фармацевтические композиции, содержащие активное вещество | |
| JP7564896B2 (ja) | 医薬組成物 | |
| EP2404588A1 (en) | Package of solid pharmaceutical preparation | |
| EP2949319A1 (en) | Pharmaceutical compositions comprising an active agent | |
| JP2024111312A (ja) | 医薬品 | |
| JP2014034574A (ja) | 医薬 |